Listen to The Lancet Gastroenterology & Hepatology: Recent Episodes
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology is a monthly journal that considers original research, reviews, and personal views in gastroenterology and hepatology from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue.
Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.
How does acute kidney injury presentation and management differ globally for patients hospitalised with cirrhosis? We spoke to Salvatore Piano, corresponding author of the landmark International Club of Ascites GLOBAL AKI study, about new data on regional variations in severity, phenotype, treatment, and outcomes across 5 continents.
John Chia discusses the results of the ASCOLT trial, which explored the effect of aspirin after completion of standard adjuvant therapy for patients with colorectal cancer.
Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.
Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.
Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.
Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.
Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.
Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.
Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.
Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.
Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.
Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.
Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.
Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.
Joep Ijspeert (Amsterdam University Medical Center) discusses a population-based study exploring the detection of proximal serrated polyps and interval post-colonoscopy colorectal cancer risk.
Elise Meima-van Praag (Amsterdam University Medical Centre) discusses the PISA-II trial, investigating short-term anti-TNF therapy with surgical closure versus anti-TNF therapy for perianal fistulas in Crohn's disease.
Juan Pablo Arab (Catholic University of Chile) discusses the current burden of NAFLD and the landscape of public health policies related to the disease in the Americas.
Sarah Blach (CDA Foundation) summarises the latest analysis of global hepatitis C virus epidemiology and cascade of care by the Polaris Observatory HCV Collaborators.
Sunil Solomon (Johns Hopkins University) discusses a study of a minimal monitoring approach for treating patients with hepatitis C virus infection.
Rupert Leong (University of Sydney) discusses a new double-blind, randomised, placebo-controlled trial of oral faecal microbiota transplantation for patients with active ulcerative colitis.
Swati Patel (University of Colorado Anschutz Medical Center) discusses the epidemiology, clinical features, biology, risk factors, and opportunities for prevention and detection of early-onset colorectal cancers.
Emilie Breekveldt (Erasmus Medical Center, Netherlands) discusses a new analysis of the faecal immunochemical testing-based colorectal screening programme in the Netherlands.
Wendy Spearman (University of Cape Town) discusses a Series on the emergence of non-alcoholic fatty liver disease in Sub-Saharan Africa and the challenges it presents.
Tim Vanuytsel (University of Leuven) discusses a new trial of spore-forming probiotics in functional dyspepsia.
Raymond Henderson (Queen’s University Belfast) discusses a new analysis of the economic burden of colorectal cancer in Europe.
Sigurður Ólafsson (Landspitali University Hospital) discusses newly published results from the nationwide programme to eliminate hepatitis C virus in Iceland.
Caroline Ovadia (King’s College London) discusses an individual participant data meta-analysis on the treatment of intrahepatic cholestasis of pregnancy with ursodeoxycholic acid.
Matthew Akiyama (Montefiore Medical Center and Albert Einstein College of Medicine, USA) discusses a Review on hepatitis C elimination among people incarcerated in prisons.
Monika Sarkar (University of California San Francisco, USA) discusses her Comment on reproductive health in women with chronic liver disease.
Ola Olén discusses the assesment of colorectal cancer risk in patients with Crohn's disease.
Dr Akbar Waljee discusses findings from a cohort study investigating the risk of cancer recurrence or a new primary cancer in patients with IBD, rheumatoid arthritis, or psoriasis who received anti-TNFα therapy.
Dr Kushala Abeysekara discusses research looking at the prevalence of non-alcoholic fatty liver disease in young adults in England.
Professor Alexander Ford discusses a meta analysis comparing different traditional treatments for irritable bowel syndrome.
Dr. Elisa Pose discusses the potential beneficial effects of statins on the treatment of patients with decompensated cirrhosis
Mohsen Naghavi describes the key findings from two new Global Burden of Disease studies investigating the global burden of pancreatic cancer and colorectal cancer.
Viktor Wintzell joins The Lancet Gastroenterology & Hepatology to discuss the risk of serious infection after use of tumour necrosis factor-α inhibitors in children with inflammatory bowel disease.
Daniel Lambrichts joins The Lancet Gastroenterology & Hepatology to discuss different treatments for diverticulitis.
Dr Olga Aroniaidis discusses the results of a newly published trial of FMT to treat IBS.
Dr Eric Jelovsek discusses new research into the treatment of this important and often overlooked condition.
Philippa Easterbrook discusses a series of two Review articles on viral hepatitis in children and adolescents.
Stuart Taylor discusses the results of the STREAMLINE trials, which assessed the use of whole-body MRI to stage colorectal and lung cancers.
Dr Rahim Naimi discusses the results of a phase 2 trial of glepaglutide to treat short bowel syndrome.
Bart Rijnders discusses his recent work on the treatment of people with acute hepatitis C.
Jennifer Flemming talks with The Lancet Gastroenterology & Hepatology about recent developments in the field of chronic liver disease.
Graham Foster speaks with The Lancet Gastroenterology & Hepatology about his recent work on incentivising and supporting primary-care physicians to increase hepatitis screenings of migrant populations.
Behzad Hajarizadeh joins The Lancet Gastroenterology and Hepatology to discuss his work with direct-acting antiviral treatments for hepatitis C among people inject drugs.
Michele Reni speaks with The Lancet Gastroenterology & Hepatology about the PAXG regimen for treatment of pancreatic cancer.
Marco Carbone talks to The Lancet Gastroenterology & Hepatology about predicting treatment response for patients with primary biliary cholangitis
Homie Razavi and Devin Razavi-Shearer join The Lancet Gastroenterology & Hepatology to discuss their HBV modelling study.
Jasper Vleugels joins The Lancet Gastroenterology and Hepatology to discuss the results of the FIND-UC trial.
Imran Aziz discusses his paper on functional dyspepsia, which is published in the April issue of The Lancet Gastroenterology & Hepatology.
In this Lancet Gastroenterology & Hepatology podcast, Johannes Vermehren discusses the risks of Hepatitis B reactivation in coinfected patients receiving treatment for Hepatitis C.
Sandra Andorf and Kari Nadeau discuss their work on anti-IgE treatment with oral immunotherapy in multifood allergic participants.
Jeffrey Hyams discusses the PROTECT study, which looks at outcomes in paediatric ulcerative colitis.
Yeng Ang and James Britton discuss setting research priorities for future work in Barrett's oesophagus and gastro-oesophageal reflux disease
Adrian Miranda talks about his work on using neurostimulation as a method for addressing abdominal pain-related functional gastrointestinal disorders in children.
Mark Fox talks about development of a solid meal test for diagnosing oesophageal motility disorders.
Federico Aucejo talks about his HALT-HCC score, which assesses risk for patients with hepatocellular carcinoma awaiting liver transplant.
Nick Sheron covers the public health and clinical problems presented by alcohol-related liver disease, and discusses what can be achieved with early intervention.
James Lindsay discusses his article on autologous stem-cell transplantation in treatment-refractory Crohn's disease.
Leo Katsidzira talks about the epidemiology of colorectal cancer in sub-Saharan Africa.
As part of The Lancet Gastroenterology & Hepatology’s April issue, Nigel Hall discusses the CHINA trial of observation versus interval appendicectomy for children with an appendix mass.
Naveed Janjua discusses a study looking at the risk factors associated with hepatitis C reinfection and means to prevent it.
Magnus Simrén comprehensively reviews treatments and therapies for irritable bowel syndrome.
Rebecca Fitzgerald discusses her paper on risk stratification for patients with Barrett's oesophagus.
Gil Kaplan discusses the rise of IBD in countries that don't have a history of the disease.
Pere Ginès from the Liver Unit at the Hospital Clinic in Barcelona, Spain, discusses a Viewpoint for liver fibrosis screening in the general population.
Luigi Titomanlio from INSERM in France discusses a case control study investigating an association between functional gastrointestinal disorders and migraine.
In the first podcast for The Lancet Gastroenterology & Hepatology, Editor Rob Brierley outlines the scope of the new journal, and Jürgen Rehm discusses public health priorities for reducing population alcohol consumption.